Virax Biolabs Group Ltd
VRAX
Company Profile
Business description
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Contact
Bo’Ness Road Newhouse
BioCity Glasgow
LondonML1 5UH
GBRT: +44 2077887414
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
17
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,773.00 | 29.40 | 0.34% |
| CAC 40 | 7,665.91 | 25.64 | -0.33% |
| DAX 40 | 23,909.61 | 123.61 | -0.51% |
| Dow JONES (US) | 43,950.23 | 130.96 | 0.30% |
| FTSE 100 | 8,760.96 | 37.95 | -0.43% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,315.42 | 41.96 | 0.21% |
| Nikkei 225 | 40,487.39 | 336.60 | 0.84% |
| NZX 50 Index | 12,602.82 | 19.23 | 0.15% |
| S&P 500 | 6,183.90 | 10.83 | 0.18% |
| S&P/ASX 200 | 8,542.30 | 28.10 | 0.33% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |